This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Combat the Choppy Market With These 5 Low-Beta Stocks
by Nilanjan Banerjee
It is imperative to build a portfolio of low-beta stocks to sail through choppy market conditions. CHWY, REGN, VSTO, RGR & CICHY are the frontrunners.
Regeneron (REGN) Antibody Cocktail for COVID-19 Gets a Boost
by Zacks Equity Research
Regeneron (REGN) antibody cocktail for COVID-19 receives a boost as the Governor of Florida recommends it for COVID-19 treatment.
Lilly's (LLY) Jardiance Gets FDA Approval for Heart Failure
by Zacks Equity Research
Lilly's (LLY) Jardiance gets FDA approval for heart failure with reduced ejection fraction (HFrEF), based on data from the phase III EMPEROR-Reduced study
Why Regeneron Pharmaceuticals (REGN) Isn't Done Growing Earnings Yet
by Zacks Equity Research
If you are looking for a fast-growing stock that is still seeing plenty of opportunities on the horizon, make sure to consider Regeneron Pharmaceuticals (REGN).
Lilly (LLY) Phase III Eczema Study on Lebrikizumab Meets Goal
by Zacks Equity Research
Eli Lilly's (LLY) two phase III studies on lebrikizumab meet the primary and all key secondary endpoints.
Exelixis (EXEL) Expands Oncology Collaboration With Invenra
by Zacks Equity Research
Exelixis (EXEL) expands collaboration with Invenra to include an additional 20 targets for multi-specific antibody, antibody-drug conjugate, and other biologic candidate discovery and development.
Rigel (RIGL) COVID-19 Treatment Denied By FDA for EUA
by Zacks Equity Research
Rigel Pharmaceuticals' (RIGL) fostamatinib does not get the FDA's nod for emergency use for COVID-19. The company plans to submit data from a larger study.
Is Regeneron Pharmaceuticals (REGN) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (REGN) Outperforming Other Medical Stocks This Year?
Biotech Stock Roundup: REGN Q2 Earnings Beat, BLUE, BYSI's Updates & More
by Zacks Equity Research
The biotech sector was in focus last week on earnings results from Regeneron (REGN) and regulatory update from bluebird (BLUE) among others.
Bayer's (BAYRY) Q2 Earnings & Revenues Surpass Estimates
by Zacks Equity Research
Bayer (BAYRY) beats estimates for both earnings and revenues in the second quarter of 2021.
Company News for Aug 6, 2021
by Zacks Equity Research
Companies in the news are: REGN, HBI, K, YETI
Weekly Jobless Claims Decline
by Zacks Equity Research
Weekly Jobless Claims Decline
Initial Jobless Claims Decline, BOE Keeps Policy Unchanged
by Zacks Equity Research
Stock futures point to a higher opening today as Weekly Jobless Claims data displayed a decline.
Regeneron (REGN) Q2 Earnings Beat, REGEN-COV Boosts Performance
by Zacks Equity Research
Regeneron (REGN) beats on Q2 earnings while sales record strong year-over-year growth on solid performance of Dupixent and Eylea, and significant contribution from REGEN-COV.
Regeneron (REGN) Q2 Earnings and Revenues Top Estimates
by Zacks Equity Research
Regeneron (REGN) delivered earnings and revenue surprises of 31.97% and 31.92%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Alnylam's (ALNY) Q2 Earnings Miss Estimates, 2021 Guidance Up
by Zacks Equity Research
Alnylam (ALNY) misses Q2 estimates for earnings but beats the same for sales. The company raises revenue guidance for 2021.
Drug/Biotech Stocks Q2 Earnings Due on Aug 5: REGN, MRNA, ZTS, ILMN
by Zacks Equity Research
Let us take a look at what is in store for some of the drug/biotech stocks, which are scheduled to report on Aug 5.
Viatris (VTRS) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Investors will look forward to regular top and bottom-line numbers and updates on the merger synergies when Viatris (VTRS) reports Q2 results.
Here's How Investors Can Find Strong Medical Stocks with the Zacks ESP Screener
by Zacks Equity Research
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Will Eylea & Dupixent Drive Regeneron's (REGN) Q2 Earnings?
by Zacks Equity Research
Investors are likely to focus on the performance of Eylea and Dupixent along with other pipeline updates when Regeneron (REGN) reports second-quarter 2021 results.
Intellia (NTLA) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Investor focus is likely to be on updates on pipeline candidates, especially NTLA-2001, when Intellia (NTLA) reports second-quarter earnings.
What's in Store for Amgen (AMGN) This Earnings Season?
by Zacks Equity Research
Volume growth from Amgen's (AMGN) key drugs like Prolia, Otezla Repatha and other and biosimilars portfolio is expected to have been partially offset by biosimilar/generic competition for mature drugs.
Eli Lilly (LLY) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Higher demand for its growth drugs is likely to have offset generic competition for several other drugs and may have boosted Lilly's (LLY) second-quarter sales.
Regeneron (REGN) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Regeneron (REGN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
4 Pharma/Biotech Stocks Poised to Beat on Earnings in Q2
by Ekta Bagri
We take a look at a few pharma/biotech companies, which are poised to beat on earnings in the second quarter.